Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- 3 September 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (11), 1055-1066
- https://doi.org/10.1016/s1470-2045(13)70380-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulationBritish Journal of Haematology, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaThe New England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2007
- Clinically relevant end points and new drug approvals for myelomaLeukemia, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple MyelomaJournal of Clinical Oncology, 2004
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998